









Markets
/
Stocks
/
nasdaq-adxn
/

Addex Therapeutics Ltd

ADXN

8.990USD

-1.135-11.21%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

7.37MMarket Cap

0.97P/E TTM



Addex Therapeutics Ltd

8.990

-1.135-11.21%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

146 / 506

Overall Ranking

255 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

30.000

Target Price

+243.64%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Growing

The company is in a growing phase, with the latest annual income totaling USD 465.76K.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 8.01M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 0.92, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.04K shares, decreasing 93.22% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.77, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 453.71K, representing a year-over-year increase of 161.22%, while its net profit experienced a year-over-year increase of 57.37%.

Score

Industry at a Glance

Previous score

8.77

Change



Financials

9.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.74

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.90

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.63

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 6.38, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 1.03, which is -21.57% below the recent high of 0.81 and 135.80% above the recent low of -0.37.

Score

Industry at a Glance

Previous score

6.38

Change

0.19

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Addex Therapeutics Ltd is 30.00, with a high of 30.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.32, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 14.78 and the support level at 2.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.32

Change

-0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.403

Buy

RSI(14)

51.682

Neutral

STOCH(KDJ)(9,3,3)

44.211

Sell

ATR(14)

0.855

High Vlolatility

CCI(14)

28.153

Neutral

Williams %R

70.344

Sell

TRIX(12,20)

1.065

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

9.789

Sell

MA10

9.288

Sell

MA20

8.247

Buy

MA50

8.206

Buy

MA100

8.360

Buy

MA200

8.014

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

GAMMA Investing LLC

1.19K

+18.00%

Morgan Stanley & Co. LLC

100.00

-94.74%

Rhumbline Advisers Ltd. Partnership

72.00

-32.71%

SBI Securities Co., Ltd.

5.00

Citadel Advisors LLC

11.74K

-2.80%

J. Stern & Co. LLP

-100.00%

Armistice Capital LLC

-100.00%

Baader Bank AG

-100.00%

Jane Street Capital, L.L.C.

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.91, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.